2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1559

Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE
Abstract Number: 489

S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)
Abstract Number: 527

Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Abstract Number: 867

Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Abstract Number: 865

Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Abstract Number: 2843

Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Abstract Number: L12

Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Abstract Number: 2877

Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Abstract Number: 1800

Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)
Abstract Number: 712

Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Abstract Number: 2093

Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases
Abstract Number: 2375

Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
Abstract Number: 2360

Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 2529

Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis
Abstract Number: 2152

Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].